RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

GlaxoSmithKline PLC

A collection of news and information related to GlaxoSmithKline PLC published by this site and its partners.

Top GlaxoSmithKline PLC Articles

Displaying items 67-77
  • Eli Lilly Drug Heist One of String of Massive Warehouse Thefts Across U.S.

    One of the dudes who ripped off an estimated $90 million worth of drugs from an Eli Lilly warehouse in Enfield (the biggest such burglary in U.S. history) was part of a ring that pulled off a series of multi-million-dollar thefts in Virginia, Florida,...
  • Deals of the day -- mergers and acquisitions

    July 25 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday: ** Dell Inc founder Michael Dell raised his $24.4 billion bid by less than 1 percent just hours before it was to be put to a vote,...
  • Things to know for Monday

    Things to know for Monday
    More than a dozen firefighters in Arizona died this weekend, political demonstrations in Brazil were suppressed by more than 10,000 troops, and Egypt is seeing resurgent political demonstrations of its own. Welcome to your post-weekend trends report for...
  • Glaxo anti-cancer cocktail gets regulatory approval

    Glaxo anti-cancer cocktail gets regulatory approval
    After her melanoma, Cheryl Stratos is mostly back to a normal life, running a business and driving her teenage son to weekend events, but there are reminders that it could all come back: The sores all over her body, the high fevers, the hair loss --...
  • Pointing to threat, pulling in profit

    Pointing to threat, pulling in profit
    WASHINGTON -- Over the last decade, former Navy Secretary Richard J. Danzig, a prominent lawyer, presidential advisor and biowarfare consultant to the Pentagon and the Department of Homeland Security, has urged the government to counter what he called a...
  • Human Genome to lay off 97 workers

    Human Genome Sciences Inc., which was acquired for $3.6 billion by London-based GlaxoSmithKline Plc in August, intends to lay off 97 employees in mid-December, and an additional but unspecified number of cuts are planned for next year, the company...
  • State AG sues maker of diabetes drugs for false advertising

    State AG sues maker of diabetes drugs for false advertising
    Maryland Attorney General Douglas F. Gansler said Wednesday he has filed a lawsuit against GlaxoSmithKline, LLC for falsely saying three of its diabetes drugs were better than others on the market. The company also withheld data that showed the drugs...
  • NIH: Herpes vaccine doesn't help women

    NIH: Herpes vaccine doesn't help women
    (Reuters) - GlaxoSmithKline's herpes vaccine failed to protect women against the virus in a trial, the U.S. National Institutes of Health said Thursday, and the company said it was stopping development of the product. The test of 8,000 women in the U.S....
  • Consolidation wave poised to hit state's health care services, biopharma sectors

    Like a one-two punch, two major Maryland employers in the health care service and pharmaceutical industries were the targets last week of multibillion-dollar acquisition deals. Both homegrown companies — Human Genome Sciences Inc. and Catalyst...
  • Expectations affect benefits of pain drug

    Expectations affect benefits of pain drug
    People who don't believe their pain medicine will work can actually reduce or even cancel out the effectiveness of the drug, and images of their brains show how they are doing it, scientists report. Researchers from Britain and Germany used brain scans...
  • Tailored breast cancer drugs in focus at cancer meet

    Tailored breast cancer drugs in focus at cancer meet
    ZURICH (Reuters) - Doctors and investors at a cancer conference starting on Friday will be keen to find out more on the effectiveness of two promising new breast cancer drugs from Swiss drugmakers Roche and Novartis. Roche's T-DM1 and Novartis's Afinitor...